Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Kiser JJ, Zhu R, DʼArgenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV.

Ther Drug Monit. 2012 Aug;34(4):446-51. doi: 10.1097/FTD.0b013e31825c4bc3.


The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV.

J Clin Pharmacol. 2012 Apr;52(4):511-9. doi: 10.1177/0091270011402826. Epub 2011 May 10.


Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Bekker A, Schaaf HS, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesseling AC.

Antimicrob Agents Chemother. 2014;58(4):2229-34. doi: 10.1128/AAC.01532-13. Epub 2014 Feb 3.


The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS.

Eur J Clin Pharmacol. 2007 Jul;63(7):633-9. Epub 2007 May 16.


Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.


Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.

Verhagen LM, López D, Hermans PW, Warris A, de Groot R, García JF, de Waard JH, Aarnoutse RE.

Trop Med Int Health. 2012 Dec;17(12):1449-56. doi: 10.1111/tmi.12003. Epub 2012 Oct 24.


Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.

Ramachandran G, Kumar AK, Bhavani PK, Kannan T, Kumar SR, Gangadevi NP, Banurekha VV, Sekar L, Ravichandran N, Mathevan G, Sanjeeva GN, Dayal R, Swaminathan S.

Antimicrob Agents Chemother. 2015 Feb;59(2):1162-7. doi: 10.1128/AAC.04338-14. Epub 2014 Dec 8.


Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.

Requena-Méndez A, Davies G, Waterhouse D, Ardrey A, Jave O, López-Romero SL, Ward SA, Moore DA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7164-70. doi: 10.1128/AAC.03258-14. Epub 2014 Sep 15.


Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR.

Arch Dis Child. 2005 Jun;90(6):614-8.


Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR.

Clin Infect Dis. 2009 Jun 1;48(11):1547-53. doi: 10.1086/598192.


Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).

Maslow JN, Mikota SK, Zhu M, Isaza R, Peddie LR, Dunker F, Peddie J, Riddle H, Peloquin CA.

J Vet Pharmacol Ther. 2005 Feb;28(1):21-7.


Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Swaminathan S.

Int J Tuberc Lung Dis. 2013 Jun;17(6):800-6. doi: 10.5588/ijtld.12.0628.


Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis.

Thee S, Detjen AA, Wahn U, Magdorf K.

Scand J Infect Dis. 2010 Apr;42(4):294-8. doi: 10.3109/00365540903493731.


Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis.

Roy V, Gupta D, Gupta P, Sethi GR, Mishra TK.

Int J Tuberc Lung Dis. 2010 Mar;14(3):374-6.


Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Zvada SP, Denti P, Donald PR, Schaaf HS, Thee S, Seddon JA, Seifart HI, Smith PJ, McIlleron HM, Simonsson US.

J Antimicrob Chemother. 2014 May;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31.


Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.

Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.


Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.

Bing C, Xiaomeia C, Jinhenga L.

Drug Metabol Drug Interact. 2011;26(3):113-8. doi: 10.1515/DMDI.2011.016.


Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid.

Cilliers K, Labadarios D, Schaaf HS, Willemse M, Maritz JS, Werely CJ, Hussey G, Donald PR.

Acta Paediatr. 2010 May;99(5):705-10. doi: 10.1111/j.1651-2227.2010.01696.x. Epub 2010 Feb 8.


Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases.

Tuberculosis Research Centre, Indian Council of Medical Research (ICMR), Chennai, India.

Int J Tuberc Lung Dis. 2011 Jun;15(6):782-8. doi: 10.5588/ijtld.09.0327.


Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US.

Br J Clin Pharmacol. 2011 Jul;72(1):51-62. doi: 10.1111/j.1365-2125.2011.03940.x.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk